PD-L1 como fator preditivo e prognóstico do câncer de mama

Detalhes bibliográficos
Autor(a) principal: Lacerda, Victor de Lima
Data de Publicação: 2020
Tipo de documento: Trabalho de conclusão de curso
Idioma: por
Título da fonte: Repositório Institucional da Universidade Cruzeiro do Sul
Texto Completo: https://repositorio.cruzeirodosul.edu.br/handle/123456789/1418
Resumo: Introdução: O câncer de mama apresenta grande protagonismo na morbimortalidade mundial, uma vez que é um dos cânceres com maior incidência e prevalência nas mulheres. Sendo assim, faz-se preciso esclarecer e debater tópicos atuais acerca dessa patologia, como a expressão de receptores PD-L1 pelas células neoplásicas, cujo valor preditivo e prognóstico vem sendo bastante discutido na atualidade. Objetivos: Compreender a importância da pesquisa dos receptores PD-L1 como fator preditivo à terapia oncológica no câncer de mama, bem como sua interferência no prognóstico dessas neoplasias. Materiais e Métodos: Trata-se de uma revisão bibliográfica, com abordagem descritiva, utilizando-se as bases de dados eletrônicas Scientific Eletronic Library Online (SCIELO) e National Library of Medicine (PUBMED, composta por artigos científicos publicados entre 2015 a 2020, escritos nas línguas portuguesa, inglesa e espanhola, que abordaram o valor preditivo ou prognóstico das proteínas PD-L1 no câncer de mama. Resultados: Foram incluídos 43 estudos nessa revisão de literatura. A alta expressão do PD-L1 por células tumorais ou imunes esteve associada a maior resposta à imunoterapia anti-PD-L1 e a certas características patológicas de pior prognóstico, mas com impacto controverso na sobrevida das pacientes. Conclusão: Devido à grande heterogeneidade dos estudos, faz-se necessário a realização de padronização nas pesquisas subsequentes para validar o papel do PD-L1 como biomarcador de resposta à terapia oncológica da mama e entender seu real valor prognóstico nessa população.
id UNICSUL-1_d6a4304a316043b4a26d6a62379e40a2
oai_identifier_str oai:repositorio.cruzeirodosul.edu.br:123456789/1418
network_acronym_str UNICSUL-1
network_name_str Repositório Institucional da Universidade Cruzeiro do Sul
repository_id_str
spelling 2021-01-28T19:29:27Z2021-01-292021-01-28T19:29:27Z2020-07-29https://repositorio.cruzeirodosul.edu.br/handle/123456789/1418Introdução: O câncer de mama apresenta grande protagonismo na morbimortalidade mundial, uma vez que é um dos cânceres com maior incidência e prevalência nas mulheres. Sendo assim, faz-se preciso esclarecer e debater tópicos atuais acerca dessa patologia, como a expressão de receptores PD-L1 pelas células neoplásicas, cujo valor preditivo e prognóstico vem sendo bastante discutido na atualidade. Objetivos: Compreender a importância da pesquisa dos receptores PD-L1 como fator preditivo à terapia oncológica no câncer de mama, bem como sua interferência no prognóstico dessas neoplasias. Materiais e Métodos: Trata-se de uma revisão bibliográfica, com abordagem descritiva, utilizando-se as bases de dados eletrônicas Scientific Eletronic Library Online (SCIELO) e National Library of Medicine (PUBMED, composta por artigos científicos publicados entre 2015 a 2020, escritos nas línguas portuguesa, inglesa e espanhola, que abordaram o valor preditivo ou prognóstico das proteínas PD-L1 no câncer de mama. Resultados: Foram incluídos 43 estudos nessa revisão de literatura. A alta expressão do PD-L1 por células tumorais ou imunes esteve associada a maior resposta à imunoterapia anti-PD-L1 e a certas características patológicas de pior prognóstico, mas com impacto controverso na sobrevida das pacientes. Conclusão: Devido à grande heterogeneidade dos estudos, faz-se necessário a realização de padronização nas pesquisas subsequentes para validar o papel do PD-L1 como biomarcador de resposta à terapia oncológica da mama e entender seu real valor prognóstico nessa população.Introduction: Breast cancer plays a major role in global morbidity and mortality, since it is one of the cancers with the highest incidence and prevalence in women. Therefore, it is necessary to clarify and debate current topics about this pathology, such as the expression of PD-L1 receptors by neoplastic cells, whose predictive and prognostic value has been widely discussed today. Objectives: To understand the importance of research on PD-L1 receptors as a predictive factor for cancer therapy in breast cancer, as well as its interference in the prognosis of these neoplasms. Materials and Methods: This is a bibliographic review, with a descriptive approach, using the electronic databases Scientific Electronic Electronic Library Online (SCIELO) and National Library of Medicine (PUBMED), composed of scientific articles published between 2015 and 2020, written in Portuguese, English and Spanish, which addressed the predictive or prognostic value of PD-L1 proteins in breast cancer. Results: 43 studies were included in this literature review. High expression of PD-L1 by tumor or immune cells was associated with a greater response to anti-PD-L1 immunotherapy and certain pathological characteristics with a worse prognosis, but with controversial impact on patient survival. Conclusion: Due to the great heterogeneity of the studies, it is necessary to carry out standardization in subsequent studies to validate the role of PD-L1 as a biomarker of response to breast cancer therapy and to understand its real prognostic value in this population.porCentro Universitário de João PessoaUNIPÊBrasilCNPQ::CIENCIAS DA SAUDE::MEDICINANeoplasias da mamaPrognósticoPatologiaPD-L1 como fator preditivo e prognóstico do câncer de mamainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bachelorThesisLima Júnior, Álvaro Ferreirahttp://lattes.cnpq.br/1309264770228155http://lattes.cnpq.br/3793961564592384Lacerda, Victor de LimaADAMS, S. et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Annals of Oncology, [s. l.], v. 30, ed. 3, p. 397-404, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30475950. Acesso em: 4 maio 2020. AFKHAMI, Michelle et al. Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. PLoS One, [s. l.], v. 14, ed. 11, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31693690. Acesso em: 4 maio 2020. AIERKEN, N et al. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. International Journal of Biological Sciences, [s. l.], v. 13, ed. 9, p. 1172-1179, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29104508. Acesso em: 1 maio 2020. ALI, Hamid Haza et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, Dordrecht, v. 26, n. 7, p. 1488–1493, 2015. Disponível em: https://academic.oup.com/annonc/article/26/7/1488/165351. Acesso em: 12 out. 2019. ALMEIDA, Ana Maria de et al. Mulheres com câncer de mama: um estudo de morbidade. Acta Oncológica Brasileira, São Paulo, v. 22, n. 2, p. 263-269, 2002. AMERICAN CANCER SOCIETY. Immune checkpoint inhibitors to treat cancer. [S. l.], 2018. Disponível em: http://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Acesso em: 16 out. 2019. ASANO, Yuka et al. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. Journal of Translational Medicine, [s. l.], v. 16, ed. 1, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29615063. Acesso em: 3 maio 2020. AZAMBUJA, Evandro de. Marcadores prognósticos e preditivos e sua importância na individualização do tratamento de pacientes com câncer de mama. Orientador: Sérgio Saldanha Menna Barreto. 2007. Tese de Doutorado (Programa de Pós-Graduação em Medicina: Ciências Médicas) - Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, [S. l.], 2007. Disponível em: https://www.lume.ufrgs.br/bitstream/handle/10183/8965/000592361.pdf?sequence=1. Acesso em: 3 out. 2019. BAE, Sang Byung et al. Expression of Programmed Death Receptor Ligand 1 with High TumorInfiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. Journal of Breast Cancer, [s. l.], v. 19, ed. 3, p. 242-251, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27721873. Acesso em: 1 maio 2020. BAPTISTA, Maurício Zuccolotto et al. titic significance of PD-L1 and PD-L2 in breast cancer. Human Pathology, Philadelphia, v. 47, n. 1, p. 78-84, 2016. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0046817715003433. Acesso em: 14 out. 2019. BEATTY, Gregory L.; GLADNEY, Whitney L. Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. Clinical Cancer Research, Philadelphia, v. 21, n. 4, p. 687-692, 2014. Disponível em: https://clincancerres.aacrjournals.org/content/21/4/687.article-info. Acesso em: 12 out. 2019. BECKERS, Rhiannon K et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology , [s. l.], v. 69, ed. 1, p. 25-34, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26588661. Acesso em: 5 maio 2020. BERGMANN, Anke; MATTOS, Inês Echenique; KOIFMAN, Rosalina Jorge; KOIFMAN, Sérgio. Morbidade após o tratamento para câncer de mama. Fisioterapia Brasil, São Paulo, v. 1, n. 2, p. 101-108, 2000. Disponível em: http://www.portalatlanticaeditora.com.br/index.php/fisioterapiabrasil/article/view/619/1263. Acesso em: 12 out. 2019. BERTUCCI, François et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget, [s. l.], v. 6, ed. 15, p. 13506-13519, 2015. Disponível em: https://www.oncotarget.com/article/3642/text/. Acesso em: 5 maio 2020. BOING, Antônio Fernando; VARGAS, Silvia Angélica López; BOING, Alexandra Crispim. A carga das neoplasias no Brasil: mortalidade e morbidade hospitalar entre 2002-2004. Revista Associação Médica Brasileira, São Paulo, v. 53, n. 4, p. 317-322, Aug. 2007. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302007000400016. Acesso em: 12 out. 2019. BOTTI, Gerardo et al. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. International Journal of Molecular Science, [s. l.], v. 8, ed. 2, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28230773. Acesso em: 1 maio 2020. CAVALLO, Federica et al. 2011: the immune hallmarks of cancer. Cancer Immunology, Immunotherapy, [s. l.], v. 60, n. 3, p. 319–326, 2011. Disponível em: https://link.springer.com/article/10.1007/s00262-010-0968-0. Acesso em: 16 out. 2019. CERBELLI, Bruna et al. PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?. BioMed Research International, [s. l.], 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29387716. Acesso em: 1 maio 2020. CHEN, Lieping; HAN, Xue. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. The Journal of Clinical Investigation, New York, v. 125, n. 9, p. 3384-3391, 2015. Disponível em: https://www.jci.org/articles/view/80011. Acesso em: 12 out. 2019. CHEN, Sheng et al. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. International Journal of Cancer, [s. l.], v. 140, ed. 6, p. 1384-1395, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27925176. Acesso em: 1 maio 2020. CHOI, Seo Hee et al. Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer. American Journal of Clinical Oncology, [s. l.], 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29419531. Acesso em: 9 maio 2020. CIRQUEIRA, Magno Belém et al. Subtipos moleculares do câncer de mama. FEMINA, [S. l.], v. 39, n. 10, p. 499-503, 2011. DAI, Suya et al. The PD-1/PD-Ls pathway and autoimmune diseases. Cellular Immunology, New York, v. 290, n. 1, p. 72–79, 2014. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/24908630. Acesso em: 16 out. 2019. DILL, Erik A. et al. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors. The American Journal of Surgical Pathology, [s. l.], v. 41, ed. 3, p. 334-342, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28195880. Acesso em: 3 maio 2020. DIRIX, Luc Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Research and Treatment, Dordrecht, v. 167, n. 3, p. 671–686, 2018. Disponível em: https://link.springer.com/article/10.1007/s10549-017-4537-5. Acesso em: 12 out. 2019. DOĞUKAN, R. et al. Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients. European Journal of Breast Health, [s. l.], v. 15, ed. 4, p. 235-241, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31620682. Acesso em: 9 maio 2020. EMENS, Leisha A. et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncology, [s. l.], v. 5, ed. 1, p. 74-82, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30242306. Acesso em: 2 maio 2020. EROL, Timuçin et al. Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival. Medicine, [s. l.], v. 98, ed. 33, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31415379. Acesso em: 2 maio 2020. EVANGELOU, ZOI et al. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old. In Vivo, [s. l.], v. 34, ed. 2, p. 639-647, 2020. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/32111764. Acesso em: 4 maio 2020. EXMAN, Pedro; GARRIDO-CASTRO, Ana C.; TOLANEY, Sara M. PD-L1 Testing in Patients with Breast Cancer: Controversies and Current Practice. Current Breast Cancer Reports, [S. l.], v. 11, p. 353–357, 2019. GHONCHEH, Mahshid; POURNAMDAR, Zahra; SALEHINIYA, Hamid. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pacific Journal of Cancer Prevention, Bangkok, v. 17, p. 43-46, 13 out. 2019. GUBIN, Matthew M.; SCHREIBER, Robert D. The odds of immunotherapy success. Science, Washington, v. 350, p. 158-159, 2015. Disponível em: https://science.sciencemag.org/content/350/6257/158/tab-pdf. Acesso em: 14 out. 2019. GUO, Lei et al. PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. Springerplus, [s. l.], v. 5, ed. 1, p. 805, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27390646. Acesso em: 1 maio 2020. GUO, Yi-Ke et al. Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis. PLoS One, San Francisco, v. 11, n. 5, p. e0156323, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27227453. Acesso em: 16 out. 2019. HE, Jing et al. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. American Journal of Clinical Pathology, [s. l.], v. 149, ed. 3, p. 253-261, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29425258. Acesso em: 1 maio 2020. HERBST, R.S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, London, v. 515, p. 563-567, 2014. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25428504. Acesso em: 16 out. 2019. HOU, Yanjun et al. D-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. The Breast Journal, [s. l.], v. 24, ed. 6, p. 911-919, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30230111. Acesso em: 7 maio 2020. HUANG, Wenfa et al. Prognostic and clinicopathological value of PD L1 expression in primary breast cancer: a meta analysis. Breast Cancer Research and Treatment , [s. l.], v. 178, ed. 1, p. 17-33, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31359214. Acesso em: 2 maio 2020. HUMPHRIES, Matthew P. et al. Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology, [s. l.], 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30651729. Acesso em: 9 maio 2020. INSTITUTO NACIONAL DO CÂNCER. Estimativa dos Casos Novos. [S. l.], 2018. Disponível em: http://www1.inca.gov.br/estimativa/2018/casos-taxas-brasil.asp. Acesso em: 16 out. 2019. IWATA, Hiroji et al. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Japanese Journal of Clinical Oncology, [s. l.], v. 49, ed. 12, p. 1083-1091, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31612909. Acesso em: 4 maio 2020. JOSEFSSON, Anders et al. Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Cancer Research, Baltimore, v. 76, n. 2, p. 472-479, 2015. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26554829. Acesso em: 14 out. 2019. KIM, Ahrong et al. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Scientific Reports, [s. l.], v. 7, ed. 1, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28916815. Acesso em: 1 maio 2020. KIM, Hye Min; LEE, Jinae; KOO, Ja Seung. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer, [s. l.], v. 17, ed. 1, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29041905. Acesso em: 1 maio 2020. KIM, HYUN-SOO et al. Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma. Anticancer Research, [s. l.], v. 40, ed. 3, p. 1487-1494, 2020. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/32132048. Acesso em: 4 maio 2020. KUROZUMI, Sasagu et al. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Scientific Reports, [s. l.], v. 9, ed. 1, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31723167. Acesso em: 3 maio 2020. LEE, Jieun; KIM, Dong-Min; LEE, Ahwon. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer. Cancer Research and Treatment, [s. l.], v. 51, ed. 2, p. 649-663, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30064200. Acesso em: 2 maio 2020. LI, Fei; REN, Yi; WANG, Zhandong. Programmed death 1 Ligand 1 expression in breast cancer and its association with patients‘ clinical parameters. Journal of Cancer Research and Therapeutics, [s. l.], v. 14, ed. 1, p. 150-154, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29516978. Acesso em: 2 maio 2020. LI, Shichao; CHEN, Li; JIANG, Jun. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer. Medicine, Baltimore, v. 98, n. 16, p. e15201, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494364/. Acesso em: 16 out. 2019. LI, Xiaoxian et al. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. American Journal of Clinical Pathology, Baltimore, v. 146, n. 4, p. 496–502, 2016. Disponível em: https://academic.oup.com/ajcp/article/146/4/496/2236126. Acesso em: 14 out. 2019. LI, Yanchun et al. The role of programmed death ligand 1 and tumor infltrating lymphocytes in breast cancer overexpressing HER2 gene. Breast Cancer Research and Treatment , [s. l.], v. 170, ed. 2, p. 293-302, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29524062. Acesso em: 1 maio 2020. LI, Zhenhua et al. PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. Journal of Cancer, [s. l.], v. 7, n. 7, p. 784–793, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860794/. Acesso em: 12 out. 2019. LIU, Ming; GUO, Fukun. Recent updates on cancer immunotherapy. Precision Clinical Medicine, [s. l.], v. 1, n. 2, p. 65–74, 2018. Disponível em: https://academic.oup.com/pcm/article/1/2/65/5091513. Acesso em: 14 out. 2019. MITTENDORF, Elizabeth A. et al. PD-L1 Expression in Triple-Negative Breast -Cancer. Cancer Immunology Research, [s. l.], v. 2, n. 4, p. 361-370, 2014. Disponível em: https://cancerimmunolres.aacrjournals.org/content/2/4/361.full-text.pdf. Acesso em: 12 out. 2019. MORI, Hitomi et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget, [s. l.], v. 8, ed. 9, p. 15584-15592, 2017. Disponível em: https://www.oncotarget.com/article/14698/text/. Acesso em: 1 maio 2020. NAGARSHETH, Nisha; WICHA, Max S.; ZOU, Weiping. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature Reviews Immunology, London, v. 17, p. 559–572, 2017. Disponível em: https://www.nature.com/articles/nri.2017.49. Acesso em: 14 out. 2019. NIKBAKHSH, Novin et al. Prevalence of depression and anxiety among cancer patients. Caspian J Intern Med, Babol, v. 5, n. 3, p. 167-170, 2014. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143739/. Acesso em: 12 out. 2019. OTT, Patrick Alexander et al. Combination immunotherapy: a road map. Journal for Immunotherapy of Cancer, [s. l.], v. 5, n. 1, 2017. Disponível em: https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-017-0218-5. Acesso em: 12 out. 2019. PAPAIOANNOU, Nikos E. et al. Harnessing the immune system to improve cancer therapy. Annals of Translational Medicine, [s. l.], v. 4, n. 14, p. 261-261, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971375/. Acesso em: 14 out. 2019. PATEL, Sandip Pravin; KURZROCK, Razelle. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, Philadelphia, v. 14, n. 4, p. 847-856, 2015. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25695955. Acesso em: 12 out. 2019. POLÓNIA, António et al. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. Journal of Clinical Pathology, [s. l.], v. 70, ed. 10, p. 860-867, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28373294. Acesso em: 5 maio 2020. POSABELLA, A. et al. The expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. European Journal of Surgical Oncology, [s. l.], v. 41, ed. 1, 2015. Disponível em: https://www.sciencedirect.com/science/article/pii/S0748798314011445#!. Acesso em: 9 maio 2020. PUMO, Vitalinda et al. Psychological and sexual disorders in long-term breast cancer survivors. Cancer Manag Res, Auckland, v. 4, p. 61-65, 2012. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304333/. Acesso em: 12 out. 2019. QIN, Tao et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget, [s. l.], v. 6, ed. 32, p. 33972-33981, 2015. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26378017. Acesso em: 1 maio 2020. REN, Xinyu et al. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. Cancer Biology & Therapy, [s. l.], v. 19, ed. 5, p. 373-380, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915030/. Acesso em: 4 maio 2020. RIBAS, Antoni. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discovery, [s. l.], v. 5, n. 9, p. 915-919, 2015. Disponível em: https://cancerdiscovery.aacrjournals.org/content/5/9/915.full-text.pdf. Acesso em: 16 out. 2019. RILEY, Rachel S. et al. Delivery technologies for cancer immunotherapy. Nature Reviews Drug Discovery, London, v. 18, p. 175–196, 2019. Disponível em: https://www.nature.com/articles/s41573-018-0006-z. Acesso em: 14 out. 2019. SABATIER, Renaud et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, [s. l.], v. 6, n. 7, p. 5449–5464, 2015. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467160/. Acesso em: 14 out. 2019. SAMPAIO, RF; MANCINI, MC. Estudos de revisão sistemática: um guia para síntese criteriosa da evidência científica. Revista Brasileira de Fisioterapia, [s. l.], v. 11, n. 1, p. 83-90, 2007. Disponível em: http://www.scielo.br/pdf/rbfis/v11n1/12.pdf. Acesso em: 3 dez. 2019. SCHMID, P. et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology, [s. l.], v. 31, ed. 5, p. 569-581, 2020. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/32278621. Acesso em: 7 maio 2020. SIERRA, Katia Piton et al. Nova classificação dos carcinomas da mama: procurando o luminal A. Revista Brasileira de Ginecologia e Obstetrícia, [S. l.], v. 36, n. 12, p. 575-580, 2014. Disponível em: https://www.scielo.br/pdf/rbgo/v36n12/0100-7203-rbgo-36-12-0575.pdf. Acesso em: 12 jun. 2020. TOMIOKA, Nobumoto et al. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer, [s. l.], v. 25, ed. 1, p. 34-42, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28488168. Acesso em: 1 maio 2020. TSANG, Julia Y. S. et al. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Breast Cancer Research and Treatment, [s. l.], v. 162, ed. 1, p. 19-30, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28058578. Acesso em: 1 maio 2020. U.S. FOOD AND DRUG ADMINISTRATION. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. [S. l.], 2019. Disponível em: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative. Acesso em: 16 out. 2019. UDALL, Margarita et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagnostic Pathology, [S. l.], v. 13, n. 12, p. 1-11, 2018. UHERCIK, M. et al. Clinical Significance of PD1 and PDL1 in Human Breast Cancer. Anticancer Research, [s. l.], v. 37, ed. 8, p. 4249-4254, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28739716. Acesso em: 4 maio 2020. WALK, Eric E. et al. The Cancer Immunotherapy Biomarker Testing Landscape. Archives of Pathology & Laboratory Medicine, [S. l.], v. 144, p. 706-724, 2020. WANG, Changjun et al. Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. The Breast Journal, [s. l.], v. 23, ed. 4, p. 436-443, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28079291. Acesso em: 1 maio 2020. WANG, X. et al. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther., [s. l.], v. 9, p. 5023–5039, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990391/. Acesso em: 16 out. 2019. WANG, Zhi-Qiang et al. PD-L1 and intratumoral immune response in breast cancer. Oncotarget, [s. l.], v. 8, ed. 31, p. 51641-51651, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28881675. Acesso em: 3 maio 2020. WIMBERLY, Hallie et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research, [s. l.], v. 3, ed. 4, p. 326-332, 2015. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25527356. Acesso em: 7 maio 2020. WORLD HEALTH ORGANIZATION. Brazil Mortality From Freast Cancer. [S. l.], 2019. Disponível em: http://www-dep.iarc.fr/WHOdb/Graph2p.asp?cancer=92&sex=2&country=2070&sYear=1990&eYear=2016&age=20&agegr=25&agen=3&orientation=1&window=1&grid=1&line=2&moving=1&scale=0&submit=%A0%A0%A0Execute%A0%A0%A0. Acesso em: 16 out. 2019. WORLD HEALTH ORGANIZATION. United States Mortality From Freast Cancer. [S. l.], 2019. Disponível em: http://www-dep.iarc.fr/WHOdb/Graph2p.asp?cancer=92&sex=2&country=2450&sYear=1950&eYear=2016&age=20&agegr=25&agen=3&orientation=1&window=1&grid=1&line=2&moving=1&scale=0&submit=%A0%A0%A0Execute%A0%A0%A0. Acesso em: 16 out. 2019. XINRAN, Wang; LIU, Yueping. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Pathology - Research and Practice, [s. l.], v. 216, ed. 3, 2020. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0344033819322459. Acesso em: 9 maio 2020. YANG, Yiping. Cancer immunotherapy: harnessing the immune system to battle cancer. Journal of Clinical Investigation, New York, v. 125, n. 9, p. 3335–3337, 2015. Disponível em: https://www.jci.org/articles/view/83871. Acesso em: 16 out. 2019. ZAWLIK, I. et al. Immune checkpoints in aggressive breast cancer subtypes. Neoplasma, [s. l.], v. 63, ed. 5, p. 768-773, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27468881. Acesso em: 3 maio 2020. ZHAI, Qinglian et al. Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer. PLoS One, [s. l.], v. 14, ed. 10, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31584964. Acesso em: 3 maio 2020. ZHANG, Lin et al. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Annals of Diagnostic Pathology, [s. l.], v. 40, p. 143-151, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31096176. Acesso em: 2 maio 2020. ZHANG, Minghui et al. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget, [s. l.], v. 8, n. 19, p. 687-692, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458212/. Acesso em: 12 out. 2019. ZHOU, Zi-Qi et al. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. Journal for ImmunoTherapy of Cancer, [s. l.], v. 7, ed. 1, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31455411. Acesso em: 4 maio 2020. ZHU, Xudong et al. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Cancer Biology & Therapy, [s. l.], v. 20, ed. 8, p. 1105-1112, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30929569. Acesso em: 2 maio 2020.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da Universidade Cruzeiro do Sulinstname:Universidade Cruzeiro do Sul (UNICSUL)instacron:UNICSULORIGINALVictor de Lima Lacerda_TCC.pdfVictor de Lima Lacerda_TCC.pdfapplication/pdf575731http://dev.siteworks.com.br:8080/jspui/bitstream/123456789/1418/1/Victor%20de%20Lima%20Lacerda_TCC.pdfb5a620a813856393b4e3917a05335b68MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://dev.siteworks.com.br:8080/jspui/bitstream/123456789/1418/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52123456789/14182021-01-28 16:30:45.105oai:repositorio.cruzeirodosul.edu.br: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Repositório InstitucionalPRIhttps://repositorio.cruzeirodosul.edu.br/oai/requestmary.pela@unicid.edu.bropendoar:2021-01-28T19:30:45Repositório Institucional da Universidade Cruzeiro do Sul - Universidade Cruzeiro do Sul (UNICSUL)false
dc.title.pt_BR.fl_str_mv PD-L1 como fator preditivo e prognóstico do câncer de mama
title PD-L1 como fator preditivo e prognóstico do câncer de mama
spellingShingle PD-L1 como fator preditivo e prognóstico do câncer de mama
Lacerda, Victor de Lima
CNPQ::CIENCIAS DA SAUDE::MEDICINA
Neoplasias da mama
Prognóstico
Patologia
title_short PD-L1 como fator preditivo e prognóstico do câncer de mama
title_full PD-L1 como fator preditivo e prognóstico do câncer de mama
title_fullStr PD-L1 como fator preditivo e prognóstico do câncer de mama
title_full_unstemmed PD-L1 como fator preditivo e prognóstico do câncer de mama
title_sort PD-L1 como fator preditivo e prognóstico do câncer de mama
author Lacerda, Victor de Lima
author_facet Lacerda, Victor de Lima
author_role author
dc.contributor.advisor1.fl_str_mv Lima Júnior, Álvaro Ferreira
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/1309264770228155
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/3793961564592384
dc.contributor.author.fl_str_mv Lacerda, Victor de Lima
contributor_str_mv Lima Júnior, Álvaro Ferreira
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS DA SAUDE::MEDICINA
topic CNPQ::CIENCIAS DA SAUDE::MEDICINA
Neoplasias da mama
Prognóstico
Patologia
dc.subject.por.fl_str_mv Neoplasias da mama
Prognóstico
Patologia
description Introdução: O câncer de mama apresenta grande protagonismo na morbimortalidade mundial, uma vez que é um dos cânceres com maior incidência e prevalência nas mulheres. Sendo assim, faz-se preciso esclarecer e debater tópicos atuais acerca dessa patologia, como a expressão de receptores PD-L1 pelas células neoplásicas, cujo valor preditivo e prognóstico vem sendo bastante discutido na atualidade. Objetivos: Compreender a importância da pesquisa dos receptores PD-L1 como fator preditivo à terapia oncológica no câncer de mama, bem como sua interferência no prognóstico dessas neoplasias. Materiais e Métodos: Trata-se de uma revisão bibliográfica, com abordagem descritiva, utilizando-se as bases de dados eletrônicas Scientific Eletronic Library Online (SCIELO) e National Library of Medicine (PUBMED, composta por artigos científicos publicados entre 2015 a 2020, escritos nas línguas portuguesa, inglesa e espanhola, que abordaram o valor preditivo ou prognóstico das proteínas PD-L1 no câncer de mama. Resultados: Foram incluídos 43 estudos nessa revisão de literatura. A alta expressão do PD-L1 por células tumorais ou imunes esteve associada a maior resposta à imunoterapia anti-PD-L1 e a certas características patológicas de pior prognóstico, mas com impacto controverso na sobrevida das pacientes. Conclusão: Devido à grande heterogeneidade dos estudos, faz-se necessário a realização de padronização nas pesquisas subsequentes para validar o papel do PD-L1 como biomarcador de resposta à terapia oncológica da mama e entender seu real valor prognóstico nessa população.
publishDate 2020
dc.date.issued.fl_str_mv 2020-07-29
dc.date.accessioned.fl_str_mv 2021-01-28T19:29:27Z
dc.date.available.fl_str_mv 2021-01-29
2021-01-28T19:29:27Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/bachelorThesis
format bachelorThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://repositorio.cruzeirodosul.edu.br/handle/123456789/1418
url https://repositorio.cruzeirodosul.edu.br/handle/123456789/1418
dc.language.iso.fl_str_mv por
language por
dc.relation.references.pt_BR.fl_str_mv ADAMS, S. et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Annals of Oncology, [s. l.], v. 30, ed. 3, p. 397-404, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30475950. Acesso em: 4 maio 2020. AFKHAMI, Michelle et al. Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. PLoS One, [s. l.], v. 14, ed. 11, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31693690. Acesso em: 4 maio 2020. AIERKEN, N et al. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. International Journal of Biological Sciences, [s. l.], v. 13, ed. 9, p. 1172-1179, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29104508. Acesso em: 1 maio 2020. ALI, Hamid Haza et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, Dordrecht, v. 26, n. 7, p. 1488–1493, 2015. Disponível em: https://academic.oup.com/annonc/article/26/7/1488/165351. Acesso em: 12 out. 2019. ALMEIDA, Ana Maria de et al. Mulheres com câncer de mama: um estudo de morbidade. Acta Oncológica Brasileira, São Paulo, v. 22, n. 2, p. 263-269, 2002. AMERICAN CANCER SOCIETY. Immune checkpoint inhibitors to treat cancer. [S. l.], 2018. Disponível em: http://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Acesso em: 16 out. 2019. ASANO, Yuka et al. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. Journal of Translational Medicine, [s. l.], v. 16, ed. 1, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29615063. Acesso em: 3 maio 2020. AZAMBUJA, Evandro de. Marcadores prognósticos e preditivos e sua importância na individualização do tratamento de pacientes com câncer de mama. Orientador: Sérgio Saldanha Menna Barreto. 2007. Tese de Doutorado (Programa de Pós-Graduação em Medicina: Ciências Médicas) - Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, [S. l.], 2007. Disponível em: https://www.lume.ufrgs.br/bitstream/handle/10183/8965/000592361.pdf?sequence=1. Acesso em: 3 out. 2019. BAE, Sang Byung et al. Expression of Programmed Death Receptor Ligand 1 with High TumorInfiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. Journal of Breast Cancer, [s. l.], v. 19, ed. 3, p. 242-251, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27721873. Acesso em: 1 maio 2020. BAPTISTA, Maurício Zuccolotto et al. titic significance of PD-L1 and PD-L2 in breast cancer. Human Pathology, Philadelphia, v. 47, n. 1, p. 78-84, 2016. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0046817715003433. Acesso em: 14 out. 2019. BEATTY, Gregory L.; GLADNEY, Whitney L. Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. Clinical Cancer Research, Philadelphia, v. 21, n. 4, p. 687-692, 2014. Disponível em: https://clincancerres.aacrjournals.org/content/21/4/687.article-info. Acesso em: 12 out. 2019. BECKERS, Rhiannon K et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology , [s. l.], v. 69, ed. 1, p. 25-34, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26588661. Acesso em: 5 maio 2020. BERGMANN, Anke; MATTOS, Inês Echenique; KOIFMAN, Rosalina Jorge; KOIFMAN, Sérgio. Morbidade após o tratamento para câncer de mama. Fisioterapia Brasil, São Paulo, v. 1, n. 2, p. 101-108, 2000. Disponível em: http://www.portalatlanticaeditora.com.br/index.php/fisioterapiabrasil/article/view/619/1263. Acesso em: 12 out. 2019. BERTUCCI, François et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget, [s. l.], v. 6, ed. 15, p. 13506-13519, 2015. Disponível em: https://www.oncotarget.com/article/3642/text/. Acesso em: 5 maio 2020. BOING, Antônio Fernando; VARGAS, Silvia Angélica López; BOING, Alexandra Crispim. A carga das neoplasias no Brasil: mortalidade e morbidade hospitalar entre 2002-2004. Revista Associação Médica Brasileira, São Paulo, v. 53, n. 4, p. 317-322, Aug. 2007. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302007000400016. Acesso em: 12 out. 2019. BOTTI, Gerardo et al. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. International Journal of Molecular Science, [s. l.], v. 8, ed. 2, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28230773. Acesso em: 1 maio 2020. CAVALLO, Federica et al. 2011: the immune hallmarks of cancer. Cancer Immunology, Immunotherapy, [s. l.], v. 60, n. 3, p. 319–326, 2011. Disponível em: https://link.springer.com/article/10.1007/s00262-010-0968-0. Acesso em: 16 out. 2019. CERBELLI, Bruna et al. PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?. BioMed Research International, [s. l.], 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29387716. Acesso em: 1 maio 2020. CHEN, Lieping; HAN, Xue. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. The Journal of Clinical Investigation, New York, v. 125, n. 9, p. 3384-3391, 2015. Disponível em: https://www.jci.org/articles/view/80011. Acesso em: 12 out. 2019. CHEN, Sheng et al. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. International Journal of Cancer, [s. l.], v. 140, ed. 6, p. 1384-1395, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27925176. Acesso em: 1 maio 2020. CHOI, Seo Hee et al. Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer. American Journal of Clinical Oncology, [s. l.], 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29419531. Acesso em: 9 maio 2020. CIRQUEIRA, Magno Belém et al. Subtipos moleculares do câncer de mama. FEMINA, [S. l.], v. 39, n. 10, p. 499-503, 2011. DAI, Suya et al. The PD-1/PD-Ls pathway and autoimmune diseases. Cellular Immunology, New York, v. 290, n. 1, p. 72–79, 2014. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/24908630. Acesso em: 16 out. 2019. DILL, Erik A. et al. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors. The American Journal of Surgical Pathology, [s. l.], v. 41, ed. 3, p. 334-342, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28195880. Acesso em: 3 maio 2020. DIRIX, Luc Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Research and Treatment, Dordrecht, v. 167, n. 3, p. 671–686, 2018. Disponível em: https://link.springer.com/article/10.1007/s10549-017-4537-5. Acesso em: 12 out. 2019. DOĞUKAN, R. et al. Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients. European Journal of Breast Health, [s. l.], v. 15, ed. 4, p. 235-241, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31620682. Acesso em: 9 maio 2020. EMENS, Leisha A. et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncology, [s. l.], v. 5, ed. 1, p. 74-82, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30242306. Acesso em: 2 maio 2020. EROL, Timuçin et al. Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival. Medicine, [s. l.], v. 98, ed. 33, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31415379. Acesso em: 2 maio 2020. EVANGELOU, ZOI et al. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old. In Vivo, [s. l.], v. 34, ed. 2, p. 639-647, 2020. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/32111764. Acesso em: 4 maio 2020. EXMAN, Pedro; GARRIDO-CASTRO, Ana C.; TOLANEY, Sara M. PD-L1 Testing in Patients with Breast Cancer: Controversies and Current Practice. Current Breast Cancer Reports, [S. l.], v. 11, p. 353–357, 2019. GHONCHEH, Mahshid; POURNAMDAR, Zahra; SALEHINIYA, Hamid. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pacific Journal of Cancer Prevention, Bangkok, v. 17, p. 43-46, 13 out. 2019. GUBIN, Matthew M.; SCHREIBER, Robert D. The odds of immunotherapy success. Science, Washington, v. 350, p. 158-159, 2015. Disponível em: https://science.sciencemag.org/content/350/6257/158/tab-pdf. Acesso em: 14 out. 2019. GUO, Lei et al. PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. Springerplus, [s. l.], v. 5, ed. 1, p. 805, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27390646. Acesso em: 1 maio 2020. GUO, Yi-Ke et al. Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis. PLoS One, San Francisco, v. 11, n. 5, p. e0156323, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27227453. Acesso em: 16 out. 2019. HE, Jing et al. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. American Journal of Clinical Pathology, [s. l.], v. 149, ed. 3, p. 253-261, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29425258. Acesso em: 1 maio 2020. HERBST, R.S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, London, v. 515, p. 563-567, 2014. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25428504. Acesso em: 16 out. 2019. HOU, Yanjun et al. D-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. The Breast Journal, [s. l.], v. 24, ed. 6, p. 911-919, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30230111. Acesso em: 7 maio 2020. HUANG, Wenfa et al. Prognostic and clinicopathological value of PD L1 expression in primary breast cancer: a meta analysis. Breast Cancer Research and Treatment , [s. l.], v. 178, ed. 1, p. 17-33, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31359214. Acesso em: 2 maio 2020. HUMPHRIES, Matthew P. et al. Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology, [s. l.], 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30651729. Acesso em: 9 maio 2020. INSTITUTO NACIONAL DO CÂNCER. Estimativa dos Casos Novos. [S. l.], 2018. Disponível em: http://www1.inca.gov.br/estimativa/2018/casos-taxas-brasil.asp. Acesso em: 16 out. 2019. IWATA, Hiroji et al. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Japanese Journal of Clinical Oncology, [s. l.], v. 49, ed. 12, p. 1083-1091, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31612909. Acesso em: 4 maio 2020. JOSEFSSON, Anders et al. Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Cancer Research, Baltimore, v. 76, n. 2, p. 472-479, 2015. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26554829. Acesso em: 14 out. 2019. KIM, Ahrong et al. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Scientific Reports, [s. l.], v. 7, ed. 1, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28916815. Acesso em: 1 maio 2020. KIM, Hye Min; LEE, Jinae; KOO, Ja Seung. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer, [s. l.], v. 17, ed. 1, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29041905. Acesso em: 1 maio 2020. KIM, HYUN-SOO et al. Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma. Anticancer Research, [s. l.], v. 40, ed. 3, p. 1487-1494, 2020. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/32132048. Acesso em: 4 maio 2020. KUROZUMI, Sasagu et al. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Scientific Reports, [s. l.], v. 9, ed. 1, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31723167. Acesso em: 3 maio 2020. LEE, Jieun; KIM, Dong-Min; LEE, Ahwon. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer. Cancer Research and Treatment, [s. l.], v. 51, ed. 2, p. 649-663, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30064200. Acesso em: 2 maio 2020. LI, Fei; REN, Yi; WANG, Zhandong. Programmed death 1 Ligand 1 expression in breast cancer and its association with patients‘ clinical parameters. Journal of Cancer Research and Therapeutics, [s. l.], v. 14, ed. 1, p. 150-154, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29516978. Acesso em: 2 maio 2020. LI, Shichao; CHEN, Li; JIANG, Jun. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer. Medicine, Baltimore, v. 98, n. 16, p. e15201, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494364/. Acesso em: 16 out. 2019. LI, Xiaoxian et al. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. American Journal of Clinical Pathology, Baltimore, v. 146, n. 4, p. 496–502, 2016. Disponível em: https://academic.oup.com/ajcp/article/146/4/496/2236126. Acesso em: 14 out. 2019. LI, Yanchun et al. The role of programmed death ligand 1 and tumor infltrating lymphocytes in breast cancer overexpressing HER2 gene. Breast Cancer Research and Treatment , [s. l.], v. 170, ed. 2, p. 293-302, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/29524062. Acesso em: 1 maio 2020. LI, Zhenhua et al. PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. Journal of Cancer, [s. l.], v. 7, n. 7, p. 784–793, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860794/. Acesso em: 12 out. 2019. LIU, Ming; GUO, Fukun. Recent updates on cancer immunotherapy. Precision Clinical Medicine, [s. l.], v. 1, n. 2, p. 65–74, 2018. Disponível em: https://academic.oup.com/pcm/article/1/2/65/5091513. Acesso em: 14 out. 2019. MITTENDORF, Elizabeth A. et al. PD-L1 Expression in Triple-Negative Breast -Cancer. Cancer Immunology Research, [s. l.], v. 2, n. 4, p. 361-370, 2014. Disponível em: https://cancerimmunolres.aacrjournals.org/content/2/4/361.full-text.pdf. Acesso em: 12 out. 2019. MORI, Hitomi et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget, [s. l.], v. 8, ed. 9, p. 15584-15592, 2017. Disponível em: https://www.oncotarget.com/article/14698/text/. Acesso em: 1 maio 2020. NAGARSHETH, Nisha; WICHA, Max S.; ZOU, Weiping. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature Reviews Immunology, London, v. 17, p. 559–572, 2017. Disponível em: https://www.nature.com/articles/nri.2017.49. Acesso em: 14 out. 2019. NIKBAKHSH, Novin et al. Prevalence of depression and anxiety among cancer patients. Caspian J Intern Med, Babol, v. 5, n. 3, p. 167-170, 2014. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143739/. Acesso em: 12 out. 2019. OTT, Patrick Alexander et al. Combination immunotherapy: a road map. Journal for Immunotherapy of Cancer, [s. l.], v. 5, n. 1, 2017. Disponível em: https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-017-0218-5. Acesso em: 12 out. 2019. PAPAIOANNOU, Nikos E. et al. Harnessing the immune system to improve cancer therapy. Annals of Translational Medicine, [s. l.], v. 4, n. 14, p. 261-261, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971375/. Acesso em: 14 out. 2019. PATEL, Sandip Pravin; KURZROCK, Razelle. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, Philadelphia, v. 14, n. 4, p. 847-856, 2015. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25695955. Acesso em: 12 out. 2019. POLÓNIA, António et al. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. Journal of Clinical Pathology, [s. l.], v. 70, ed. 10, p. 860-867, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28373294. Acesso em: 5 maio 2020. POSABELLA, A. et al. The expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. European Journal of Surgical Oncology, [s. l.], v. 41, ed. 1, 2015. Disponível em: https://www.sciencedirect.com/science/article/pii/S0748798314011445#!. Acesso em: 9 maio 2020. PUMO, Vitalinda et al. Psychological and sexual disorders in long-term breast cancer survivors. Cancer Manag Res, Auckland, v. 4, p. 61-65, 2012. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304333/. Acesso em: 12 out. 2019. QIN, Tao et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget, [s. l.], v. 6, ed. 32, p. 33972-33981, 2015. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26378017. Acesso em: 1 maio 2020. REN, Xinyu et al. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. Cancer Biology & Therapy, [s. l.], v. 19, ed. 5, p. 373-380, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915030/. Acesso em: 4 maio 2020. RIBAS, Antoni. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discovery, [s. l.], v. 5, n. 9, p. 915-919, 2015. Disponível em: https://cancerdiscovery.aacrjournals.org/content/5/9/915.full-text.pdf. Acesso em: 16 out. 2019. RILEY, Rachel S. et al. Delivery technologies for cancer immunotherapy. Nature Reviews Drug Discovery, London, v. 18, p. 175–196, 2019. Disponível em: https://www.nature.com/articles/s41573-018-0006-z. Acesso em: 14 out. 2019. SABATIER, Renaud et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, [s. l.], v. 6, n. 7, p. 5449–5464, 2015. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467160/. Acesso em: 14 out. 2019. SAMPAIO, RF; MANCINI, MC. Estudos de revisão sistemática: um guia para síntese criteriosa da evidência científica. Revista Brasileira de Fisioterapia, [s. l.], v. 11, n. 1, p. 83-90, 2007. Disponível em: http://www.scielo.br/pdf/rbfis/v11n1/12.pdf. Acesso em: 3 dez. 2019. SCHMID, P. et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology, [s. l.], v. 31, ed. 5, p. 569-581, 2020. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/32278621. Acesso em: 7 maio 2020. SIERRA, Katia Piton et al. Nova classificação dos carcinomas da mama: procurando o luminal A. Revista Brasileira de Ginecologia e Obstetrícia, [S. l.], v. 36, n. 12, p. 575-580, 2014. Disponível em: https://www.scielo.br/pdf/rbgo/v36n12/0100-7203-rbgo-36-12-0575.pdf. Acesso em: 12 jun. 2020. TOMIOKA, Nobumoto et al. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer, [s. l.], v. 25, ed. 1, p. 34-42, 2018. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28488168. Acesso em: 1 maio 2020. TSANG, Julia Y. S. et al. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Breast Cancer Research and Treatment, [s. l.], v. 162, ed. 1, p. 19-30, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28058578. Acesso em: 1 maio 2020. U.S. FOOD AND DRUG ADMINISTRATION. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. [S. l.], 2019. Disponível em: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative. Acesso em: 16 out. 2019. UDALL, Margarita et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagnostic Pathology, [S. l.], v. 13, n. 12, p. 1-11, 2018. UHERCIK, M. et al. Clinical Significance of PD1 and PDL1 in Human Breast Cancer. Anticancer Research, [s. l.], v. 37, ed. 8, p. 4249-4254, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28739716. Acesso em: 4 maio 2020. WALK, Eric E. et al. The Cancer Immunotherapy Biomarker Testing Landscape. Archives of Pathology & Laboratory Medicine, [S. l.], v. 144, p. 706-724, 2020. WANG, Changjun et al. Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. The Breast Journal, [s. l.], v. 23, ed. 4, p. 436-443, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28079291. Acesso em: 1 maio 2020. WANG, X. et al. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther., [s. l.], v. 9, p. 5023–5039, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990391/. Acesso em: 16 out. 2019. WANG, Zhi-Qiang et al. PD-L1 and intratumoral immune response in breast cancer. Oncotarget, [s. l.], v. 8, ed. 31, p. 51641-51651, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28881675. Acesso em: 3 maio 2020. WIMBERLY, Hallie et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research, [s. l.], v. 3, ed. 4, p. 326-332, 2015. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25527356. Acesso em: 7 maio 2020. WORLD HEALTH ORGANIZATION. Brazil Mortality From Freast Cancer. [S. l.], 2019. Disponível em: http://www-dep.iarc.fr/WHOdb/Graph2p.asp?cancer=92&sex=2&country=2070&sYear=1990&eYear=2016&age=20&agegr=25&agen=3&orientation=1&window=1&grid=1&line=2&moving=1&scale=0&submit=%A0%A0%A0Execute%A0%A0%A0. Acesso em: 16 out. 2019. WORLD HEALTH ORGANIZATION. United States Mortality From Freast Cancer. [S. l.], 2019. Disponível em: http://www-dep.iarc.fr/WHOdb/Graph2p.asp?cancer=92&sex=2&country=2450&sYear=1950&eYear=2016&age=20&agegr=25&agen=3&orientation=1&window=1&grid=1&line=2&moving=1&scale=0&submit=%A0%A0%A0Execute%A0%A0%A0. Acesso em: 16 out. 2019. XINRAN, Wang; LIU, Yueping. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Pathology - Research and Practice, [s. l.], v. 216, ed. 3, 2020. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0344033819322459. Acesso em: 9 maio 2020. YANG, Yiping. Cancer immunotherapy: harnessing the immune system to battle cancer. Journal of Clinical Investigation, New York, v. 125, n. 9, p. 3335–3337, 2015. Disponível em: https://www.jci.org/articles/view/83871. Acesso em: 16 out. 2019. ZAWLIK, I. et al. Immune checkpoints in aggressive breast cancer subtypes. Neoplasma, [s. l.], v. 63, ed. 5, p. 768-773, 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27468881. Acesso em: 3 maio 2020. ZHAI, Qinglian et al. Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer. PLoS One, [s. l.], v. 14, ed. 10, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31584964. Acesso em: 3 maio 2020. ZHANG, Lin et al. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Annals of Diagnostic Pathology, [s. l.], v. 40, p. 143-151, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31096176. Acesso em: 2 maio 2020. ZHANG, Minghui et al. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget, [s. l.], v. 8, n. 19, p. 687-692, 2017. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458212/. Acesso em: 12 out. 2019. ZHOU, Zi-Qi et al. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. Journal for ImmunoTherapy of Cancer, [s. l.], v. 7, ed. 1, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/31455411. Acesso em: 4 maio 2020. ZHU, Xudong et al. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Cancer Biology & Therapy, [s. l.], v. 20, ed. 8, p. 1105-1112, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30929569. Acesso em: 2 maio 2020.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Centro Universitário de João Pessoa
dc.publisher.initials.fl_str_mv UNIPÊ
dc.publisher.country.fl_str_mv Brasil
publisher.none.fl_str_mv Centro Universitário de João Pessoa
dc.source.none.fl_str_mv reponame:Repositório Institucional da Universidade Cruzeiro do Sul
instname:Universidade Cruzeiro do Sul (UNICSUL)
instacron:UNICSUL
instname_str Universidade Cruzeiro do Sul (UNICSUL)
instacron_str UNICSUL
institution UNICSUL
reponame_str Repositório Institucional da Universidade Cruzeiro do Sul
collection Repositório Institucional da Universidade Cruzeiro do Sul
bitstream.url.fl_str_mv http://dev.siteworks.com.br:8080/jspui/bitstream/123456789/1418/1/Victor%20de%20Lima%20Lacerda_TCC.pdf
http://dev.siteworks.com.br:8080/jspui/bitstream/123456789/1418/2/license.txt
bitstream.checksum.fl_str_mv b5a620a813856393b4e3917a05335b68
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da Universidade Cruzeiro do Sul - Universidade Cruzeiro do Sul (UNICSUL)
repository.mail.fl_str_mv mary.pela@unicid.edu.br
_version_ 1801771131812708352

Registros relacionados